American unemployment declines to the 50-year historical low level of 3.5% with moderate job growth.

Chanel Holden

2019-11-19 09:33:00 Tue ET

American unemployment declines to the 50-year historical low level of 3.5% with moderate job growth. Despite a sharp slowdown in U.S. services and utilities, non-farm payrolls increase by 135,000-to-145,000 jobs on average per month in the current fiscal year 2019-2020. As of 2019Q4, The Economist and Reuters forecast higher U.S. non-farm payrolls in the next few quarters. As the U.S. unemployment rate tends to rise ahead of an economic recession, the recent decline in American unemployment pushes out the timeline for any potential recession into late-2020.

U.S. core inflation remain below the 2% target, and wage growth gradually declines from 3.2% to 2.9% per year. The U.S. labor market grows sustainably in the early resolution of uncertainty around the Sino-American trade conflict, Federal Reserve monetary policy reversal, Treasury fiscal stimulus, and asset price normalization for oil, gold, and the greenback etc. Several stock market analysts and investment bankers expect the U.S. economy to grow at 2%-3% per annum in 2019-2020. The reasonable real GDP momentum accords with the main stock market investment thesis that the Trump tax cuts help finance the current economic boom. U.S. fiscal stimulus hence contributes to greater economic growth, domestic job creation, and capital investment.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

U.S. presidential election: a re-match between Biden and Trump in November 2024

Dan Rochefort

2024-03-19 03:35:58 Tuesday ET

U.S. presidential election: a re-match between Biden and Trump in November 2024

U.S. presidential election: a re-match between Biden and Trump in November 2024 We delve into the 5 major economic themes of the U.S. presidential electi

+See More

Addendum on empirical tests of multi-factor models for asset return prediction

Rose Prince

2022-03-05 09:27:00 Saturday ET

Addendum on empirical tests of multi-factor models for asset return prediction

Addendum on empirical tests of multi-factor models for asset return prediction Fama and French (2015) propose an empirical five-factor asset pricing mode

+See More

The finance ministers of Britain, Canada, France, Germany, Italy, and Japan team up against U.S. President Trump at the G7 forum.

Jonah Whanau

2018-06-02 09:35:00 Saturday ET

The finance ministers of Britain, Canada, France, Germany, Italy, and Japan team up against U.S. President Trump at the G7 forum.

The finance ministers of Britain, Canada, France, Germany, Italy, and Japan team up against U.S. President Donald Trump and Treasury Secretary Steven Mnuchi

+See More

It can be practical for the U.S. to impose the 2% Warren wealth tax on the rich.

Dan Rochefort

2019-02-03 13:39:00 Sunday ET

It can be practical for the U.S. to impose the 2% Warren wealth tax on the rich.

It can be practical for the U.S. to impose the 2% wealth tax on the rich. Democratic Senator Elizabeth Warren proposes a 2% wealth tax on the richest Americ

+See More

Ben Horowitz shares many hard truths, setbacks, failures, obstacles, difficulties, and disappointments through his rare unique entrepreneurial journey at LoudCloud.

Laura Hermes

2025-05-29 08:25:28 Thursday ET

Ben Horowitz shares many hard truths, setbacks, failures, obstacles, difficulties, and disappointments through his rare unique entrepreneurial journey at LoudCloud.

Serial venture capitalist Ben Horowitz describes many hard truths, lessons, and insights from his entrepreneurial journey of running LoudCloud from a Silico

+See More